Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Lithium Americas Corp (LAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Lithium Americas Corp — how do they compare? Hinge Health Inc. Class A Common Stock trades at $103.96 (market cap $8.48B), while Lithium Americas Corp trades at $2.09 (market cap $800.75M). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 10.6× Lithium Americas Corp's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Lithium Americas Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Lithium Americas Corp for 27 Days on average.
| HNGE | LAC | |
|---|---|---|
Market Cap | $8.48B | $800.75M |
Volume | 879,799 | 6,634,849 |
Sector | Health | Basic Materials |
52-Week High | $105.14 | $9.44 |
52-Week Low | $31.17 | $2.07 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $8.10B | $1.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Lithium Americas (LAC) trades at $2.20, down 2.22% with bearish technical signals but positive analyst sentiment. The company shows negative profitability metrics with ROE at -9.56% and net income of -$122.09M for 2025, though it has beaten earnings expectations in recent quarters. Strong financing activity ($1.14B in 2025) supports Thacker Pass development, a key growth catalyst.
LAC presents a high-risk, high-reward opportunity with analyst consensus price target of $4.00 (82% upside). While current fundamentals are weak due to pre-revenue phase, successful execution at Thacker Pass could drive significant revaluation. Key risks include lithium price volatility, project execution challenges, and continued cash burn during development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →
